Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Pharmaceuticals topic
No spam. Unsubscribe anytime.
HCA reviews early rounds of Medicare drug price negotiations; Ozempic and Wegovy flagged for 2027
Summary
HCA summarized the Inflation Reduction Act drug price negotiation program: ten Part D drugs went into effect in 2026, more drugs are scheduled for 2027 (including GLP‑1s such as Ozempic and Wegovy) and staff will follow up with more price‑comparison data.
Laura Ryan gave a brief review of the Medicare drug price negotiation program established by the Inflation Reduction Act. She said the first negotiated Part D prices for ten drugs took effect at the start of the year and that additional lists are set for 2027 and 2028. Ryan identified GLP‑1 agents such as Ozempic and Wegovy among the 2027 list and said staff would return with analysis comparing pre‑negotiation and post‑negotiation prices.
"Probably of great interest is going to be Ozempic, Wegovy on that list," Ryan said, noting the agency will analyze how negotiated prices affect plan costs, out‑of‑pocket liability and overall drug spend in PEB plans. Board members asked staff to provide comparative data on prior prices and the negotiated prices once available and to overlay negotiation targets with the program's top drug spend list to show potential plan impacts.
